Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. Established by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases who are so often underserved.
In August of 2019, Harmony Biosciences received FDA approval for its first commercial product, WAKIX® (pitolisant) tablets. Harmony is currently evaluating pitolisant for broader applications in neurological disorders that may be mediated by the H3 receptor. See product pipeline for further details.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
Jun 10, 2021
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
Jun 09, 2021
Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
Jun 07, 2021